OBJECTIVES: To perform MRI cerebellum volumetry in @entity1 exposed to @entity3174 and to identify factors associated with @entity76 ( @entity76 ). METHODS: From 100 consecutive @entity302 @entity1 we selected those with @entity3174 use for more than 2 months and with MRI scan available for volumetric studies. We obtained cerebellar volumes corrected for total intracranial volume. Volumes below 2 standard deviations from the mean of control group were considered abnormal. RESULTS: We studied 56 @entity1 (33 @entity1 ). Mean age was 33.6 years and mean duration of @entity302 was 17.6 years. Mean daily dose of @entity3174 was 301 mg. @entity76 was detected in 20 (35.7%) @entity1 . @entity76 was not associated with frequent generalised @entity410 . @entity76 correlated with duration of @entity302 (r=-0.34; P=0.01) and years of treatment with @entity3174 (r=-0.48; P=0.001), but not with age and mean daily dosage of @entity3174 (P>0.05). However, a multiple correlation analysis as well as a backward stepwise multiple regression analysis including all variables showed that only duration of treatment was significantly associated with @entity76 (P=0.001). CONCLUSIONS: @entity76 is frequently associated with long-term use of @entity3174 . Although duration of @entity302 may have an influence in the @entity76 , this is clearly less important than the time of exposure to @entity3174 .

Cerebellar volume and long-term use of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity76 :: ('MESH:D002526', 'Disease') :: ['cerebellar atrophy', 'CA'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy'] @entity3174 :: ('MESH:D010672', 'Chemical') :: ['phenytoin']
@entity3174 :: (MESH:D010672,Chemical) :: ['phenytoin']
